Biological Products, (No Diagnostic Substances) — Ranked by Total Assets
SIC 2836 · Annual figures from SEC 10-K filings
These rankings show the largest Biological Products, (No Diagnostic Substances) companies by total assets, based on the most recent fiscal year data reported in their annual 10-K filings with the SEC. Only companies with XBRL-tagged financial data are included. Use the tabs below to switch between revenue, net income, and total assets.
| # | Company | Total Assets | Fiscal Year |
|---|---|---|---|
| 1 | AMGEN INC AMGN | $90.59B | FY2025 |
| 2 | GILEAD SCIENCES, INC. GILD | $59.02B | FY2025 |
| 3 | BIOGEN INC. BIIB | $29.44B | FY2025 |
| 4 | Moderna, Inc. MRNA | $12.34B | FY2025 |
| 5 | NEUROCRINE BIOSCIENCES INC NBIX | $4.63B | FY2025 |
| 6 | Vaxcyte, Inc. PCVX | $3.00B | FY2025 |
| 7 | REPLIGEN CORP RGEN | $2.95B | FY2025 |
| 8 | EXELIXIS, INC. EXEL | $2.84B | FY2025 |
| 9 | BIO-TECHNE Corp TECH | $2.56B | FY2025 |
| 10 | HALOZYME THERAPEUTICS, INC. HALO | $2.53B | FY2025 |
| 11 | Revolution Medicines, Inc. RVMDW | $2.35B | FY2025 |
| 12 | CRISPR Therapeutics AG CRSP | $2.27B | FY2025 |
| 13 | Kymera Therapeutics, Inc. KYMR | $1.74B | FY2025 |
| 14 | Beam Therapeutics Inc. BEAM | $1.48B | FY2025 |
| 15 | RECURSION PHARMACEUTICALS, INC. RXRX | $1.47B | FY2025 |
| 16 | Krystal Biotech, Inc. KRYS | $1.33B | FY2025 |
| 17 | NOVAVAX INC NVAX | $1.18B | FY2025 |
| 18 | Denali Therapeutics Inc. DNLI | $1.14B | FY2025 |
| 19 | Ginkgo Bioworks Holdings, Inc. DNABW | $1.12B | FY2025 |
| 20 | Immunocore Holdings plc IMCR | $1.07B | FY2025 |
| 21 | Vir Biotechnology, Inc. VIR | $1.00B | FY2025 |
| 22 | Apogee Therapeutics, Inc. APGE | $937.13M | FY2025 |
| 23 | IOVANCE BIOTHERAPEUTICS, INC. IOVA | $913.17M | FY2025 |
| 24 | CG Oncology, Inc. CGON | $791.59M | FY2025 |
| 25 | Immunovant, Inc. IMVT | $776.22M | FY2025 |
| 26 | Twist Bioscience Corp TWST | $641.86M | FY2025 |
| 27 | ADMA BIOLOGICS, INC. ADMA | $624.24M | FY2025 |
| 28 | Relay Therapeutics, Inc. RLAY | $621.33M | FY2025 |
| 29 | Arcellx, Inc. ACLX | $603.99M | FY2025 |
| 30 | Autolus Therapeutics plc AUTL | $589.07M | FY2025 |
| 31 | 4D Molecular Therapeutics, Inc. FDMT | $566.71M | FY2025 |
| 32 | Tarsus Pharmaceuticals, Inc. TARS | $562.16M | FY2025 |
| 33 | Replimune Group, Inc. REPL | $551.33M | FY2025 |
| 34 | BIOCRYST PHARMACEUTICALS INC BCRX | $514.16M | FY2025 |
| 35 | Adaptive Biotechnologies Corp ADPT | $512.74M | FY2025 |
| 36 | ImmunityBio, Inc. IBRX | $501.90M | FY2025 |
| 37 | Vericel Corp VCEL | $487.97M | FY2025 |
| 38 | Vor Biopharma Inc. VOR | $464.13M | FY2025 |
| 39 | REGENXBIO Inc. RGNX | $453.03M | FY2025 |
| 40 | Monte Rosa Therapeutics, Inc. GLUE | $448.66M | FY2025 |
| 41 | Cullinan Therapeutics, Inc. CGEM | $448.37M | FY2025 |
| 42 | Sana Biotechnology, Inc. SANA | $416.89M | FY2025 |
| 43 | Allogene Therapeutics, Inc. ALLO | $415.91M | FY2025 |
| 44 | Scholar Rock Holding Corp SRRK | $404.27M | FY2025 |
| 45 | Maze Therapeutics, Inc. MAZE | $397.13M | FY2025 |
| 46 | Scilex Holding Co SCLXW | $364.98M | FY2025 |
| 47 | C4 Therapeutics, Inc. CCCC | $359.08M | FY2025 |
| 48 | Kodiak Sciences Inc. KOD | $351.53M | FY2025 |
| 49 | Taysha Gene Therapies, Inc. TSHA | $343.32M | FY2025 |
| 50 | Prime Medicine, Inc. PRME | $342.73M | FY2025 |